Glovadalen

Glovadalen
Clinical data
Other names	UCB-0022; UCB0022
Identifiers
	IUPAC name 2-(3,5-dichloro-1-methylindazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(2-hydroxypropan-2-yl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone;
CAS Number	2576359-31-2;
PubChem CID	155460962;
IUPHAR/BPS	13232;
UNII	H8T5VKH4CZ;
Chemical and physical data
Formula	C24H27Cl2N3O3
Molar mass	476.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1C2=C(C[C@@H](N1C(=O)CC3=C(C=CC4=C3C(=NN4C)Cl)Cl)CO)C(=CC=C2)C(C)(C)O;
	InChI InChI=1S/C24H27Cl2N3O3/c1-13-15-6-5-7-18(24(2,3)32)16(15)10-14(12-30)29(13)21(31)11-17-19(25)8-9-20-22(17)23(26)27-28(20)4/h5-9,13-14,30,32H,10-12H2,1-4H3/t13-,14+/m0/s1; Key:SVTDEVFVOSMAQQ-UONOGXRCSA-N;

Glovadalen (developmental code name UCB-0022) is a dopamine D₁ receptor positive allosteric modulator which is under development for the treatment of Parkinson's disease.^[1]^[2]^[3]^[4]^[5]^[6] It has been found to potentiate the capacity of dopamine to activate the D₁ receptor by 10-fold in vitro with no actions on other dopamine receptors.^[5]^[6] As of May 2024, glovadalen is in phase 2 clinical trials for this indication.^[1]^[2]^[5] The drug is under development by UCB Biopharma.^[1]^[4]^[5] It is described as an orally active, centrally penetrant small molecule.^[1]^[5]^[6]

References

^ ^a ^b ^c ^d "UCB 0022". AdisInsight. Springer Nature Switzerland AG. 28 May 2024. Retrieved 10 August 2024.
^ ^a ^b "Delving into the Latest Updates on Glovadalen with Synapse". Synapse. 8 August 2024. Retrieved 10 August 2024.
^ McFarthing K, Buff S, Rafaloff G, Fiske B, Mursaleen L, Fuest R, et al. (2023). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update". Journal of Parkinson's Disease. 13 (4): 427–439. doi:10.3233/JPD-239901. PMC 10357160. PMID 37302040. Our analysis of dopaminergic therapies shows a continued emphasis on DA agonists and levodopa reformulation. These include Cerevel's tavapadon, a D1/D5 receptor partial agonist and UCB0022, a positive allosteric modulator of the D1 receptor, as well as approaches to sub-cutaneously deliver levodopa/carbidopa such as Abbvie's ABBV-951 and Neuroderm's ND0612.
^ ^a ^b "Glovadalen". IUPHAR/BPS Guide to PHARMACOLOGY. Retrieved 10 August 2024.
^ ^a ^b ^c ^d ^e "UCB0022". ALZFORUM. 3 May 2024. Retrieved 10 August 2024.
^ ^a ^b ^c Vermeiren C, Ates A, Bouzom F, Delaunois A, Gillard M, Kenda B, et al. (7 September 2022). "Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)". Movement Disorders. 37 (Suppl 2 [2022 International Congress September 15-18, 2022. Madrid, Spain]). Retrieved 10 August 2024.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.